Literature DB >> 2950265

Significance of suppressor macrophages for immunosurveillance of tumor-bearing mice.

T Fujii, T Igarashi, S Kishimoto.   

Abstract

The in vivo significance of suppressor macrophages for antitumor immunity was investigated in a syngeneic tumor system. The presence of suppressor macrophages in the spleens of X5563 C3H/HeN tumor-bearing mice (TBM) was directly shown in vitro. Thus the addition of splenic macrophages of TBM suppressed the in vitro secondary induction of both tumor-specific cytotoxic T-cells and effector cells of the delayed-type hypersensitivity reaction. Splenic macrophages of TBM exerted suppression on tumor-specific T-cell-mediated cytotoxicity in the effector phase as well. Prostaglandin production was found to be one of the major mechanisms involved in macrophage-induced suppression. In vivo treatment of TBM with carrageenan and/or indomethacin retarded tumor growth and in parallel augmented cell-mediated cytotoxicity against X5563 cells, probably by affecting suppressor macrophages in vivo. The suppressive effect of splenic macrophages from TBM was clearly demonstrated in a tumor-neutralization test indicating that suppressor macrophages were able to exert their function in vivo as well as in vitro. All these results suggested that suppressor macrophages had in vivo significance for the suppression of the immunosurveillance of the hosts.

Entities:  

Mesh:

Year:  1987        PMID: 2950265

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  15 in total

Review 1.  Regulatory mechanisms of antitumor T cell responses in the tumor-bearing state.

Authors:  H Fujiwara; T Hamaoka
Journal:  Immunol Res       Date:  1995       Impact factor: 2.829

Review 2.  Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules.

Authors:  R Kiessling; K Kono; M Petersson; K Wasserman
Journal:  Springer Semin Immunopathol       Date:  1996

3.  Enhanced antiproliferative activity by metastatic RAW117 lymphoma cells.

Authors:  S S Joshi; S J O'Connor; D D Weisenburger; J G Sharp; H M Gharpure; K W Brunson
Journal:  Clin Exp Metastasis       Date:  1991 Jan-Feb       Impact factor: 5.150

4.  Immunosuppression in murine renal cell carcinoma. I. Characterization of extent, severity and sources.

Authors:  S K Gregorian; J R Battisto
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

5.  Alternatively activated macrophages actively inhibit proliferation of peripheral blood lymphocytes and CD4+ T cells in vitro.

Authors:  C Schebesch; V Kodelja; C Müller; N Hakij; S Bisson; C E Orfanos; S Goerdt
Journal:  Immunology       Date:  1997-12       Impact factor: 7.397

6.  Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses.

Authors:  M Otsuji; Y Kimura; T Aoe; Y Okamoto; T Saito
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

7.  Immunosuppression in murine renal cell carcinoma. II. Identification of responsible lymphoid cell phenotypes and examination of elimination of suppression.

Authors:  S K Gregorian; J R Battisto
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

8.  Phenotypic analysis of nylon-wool-adherent suppressor cells that inhibit the effector process of tumour cell lysis by lymphokine-activated killer cells in patients with advanced gastric carcinoma.

Authors:  S Koyama; K Fukao
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

9.  Progression mechanisms in colon cancer: soluble interleukin-2 (IL-2) receptor, IL-2 plus anti-CD3 proliferative response and tumour stage correlations.

Authors:  A M Berghella; P Pellegrini; D Piancatelli; D Maccarone; T Del Beato; D Giubilei; A Pomidori; D Adorno; C U Casciani
Journal:  Cancer Immunol Immunother       Date:  1994-03       Impact factor: 6.968

10.  Suppressor cells in the effector phase of autologous cytotoxic reactions in cancer patients.

Authors:  M Eura; T Maehara; T Ikawa; T Ishikawa
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.